...
机译:用紫杉烷基型佐剂化疗治疗的乳腺癌大队患者磷酸盐蛋白D1和P53途径与细胞周期蛋白D1和P53途径的预后价值
Iaso Womens Hosp Dept Pathol 37-39 Kifisias Ave Athens 15123 Greece;
Aristotle Univ Thessaloniki Lab Mol Oncol Hellen Fdn Canc Res Thessaloniki Greece;
Hellen Cooperat Oncol Grp Data Off Sect Biostat Athens Greece;
Univ Athens Sch Med Dept Clin Therapeut Alexandra Hosp Athens Greece;
Aristotle Univ Thessaloniki Sch Hlth Sci Fac Med Dept Med Oncol Papageorgiou Hosp Thessaloniki;
Univ Athens Sch Med Dept Med 1 Laiko Gen Hosp Athens Greece;
Metropolitan Hosp Dept Med Oncol 1 Piraeus Greece;
Univ Patras Med Sch Univ Hosp Div Oncol Dept Med Patras Greece;
Metropolitan Hosp Pathol Dept Piraeus Greece;
Aristotle Univ Thessaloniki Sch Hlth Sci Fac Med Dept Pathol Papageorgiou Hosp Thessaloniki;
Agii Anargiri Canc Hosp Dept Med Oncol 2 Athens Greece;
Univ Athens Sch Med Dept Propedeut Surg 2 Laiko Gen Hosp Athens Greece;
Hippokrateion Hosp Oncol Unit Athens Greece;
St Savvas Anticanc Hosp Pathol Dept Athens Greece;
424 Army Gen Hosp Dept Med Oncol Thessaloniki Greece;
Aristotle Univ Thessaloniki Lab Mol Oncol Hellen Fdn Canc Res Thessaloniki Greece;
Univ Patras Med Sch Univ Hosp Div Oncol Dept Med Patras Greece;
Hippokrateion Hosp Dept Internal Med 2 Oncol Sect Athens Greece;
Aristotle Univ Thessaloniki Lab Mol Oncol Hellen Fdn Canc Res Thessaloniki Greece;
Univ Athens Med Sch Pathol Dept Athens Greece;
pRB; p16; breast cancer; immunohistochemistry; chemotherapeutic agents;
机译:用紫杉烷基型佐剂化疗治疗的乳腺癌大队患者磷酸盐蛋白D1和P53途径与细胞周期蛋白D1和P53途径的预后价值
机译:鉴定具有明显预测和预后特征的生物学基础乳腺癌类型:类固醇激素和HER2受体表达在新辅助蒽环类/紫杉烷类化学治疗患者中的作用
机译:评价含着蒽环类辅助化疗的乳腺癌患者着丝粒17的获得和HER2 /拓扑异构酶IIα基因状态及蛋白表达的预后作用:两项希腊合作肿瘤小组(HeCOG)III期临床试验的合并分析
机译:HER-2和P53在紫杉烷基和蒽环类新辅助化疗的乳腺癌中的临床意义
机译:评价含着蒽环类辅助化疗的乳腺癌患者着丝粒17的获得和HER2 /拓扑异构酶IIα基因的状态及蛋白表达的预后作用:两项希腊合作肿瘤小组(HeCOG)III期临床试验的合并分析
机译:评价含着蒽环类辅助化疗的乳腺癌患者着丝粒17的获得和HER2 /拓扑异构酶IIα基因的状态及蛋白质表达的预后作用:两项希腊合作肿瘤小组(HeCOG)III期临床试验的合并分析
机译:队列研究c-erbB-2和细胞周期蛋白D1过表达,p53突变和/或蛋白质积累,以及从良性乳腺疾病进展到乳腺癌的风险;和创建良性乳腺组织